Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Azacitidine
8%
B-cell Lymphoma 2 (Bcl-2)
7%
Blast Phase
8%
Cedazuridine
5%
Chronic Myeloid Leukemia
15%
Complete Remission
20%
Confidence Interval
6%
Decitabine
23%
Enasidenib
5%
Event-free Survival
10%
FLAG-Ida
5%
FLT3 Inhibitor
6%
FLT3 mutation
6%
Frontline Treatment
6%
Gemtuzumab Ozogamicin
5%
Hazard Ratio
5%
High Risk
10%
Hypomethylating Agents
22%
Improved Outcomes
7%
Induction Chemotherapy
8%
Intensive Chemotherapy
24%
Isocitrate Dehydrogenase 1 (IDH1)
7%
Leukemia
7%
MD Anderson Cancer Center
5%
Median Overall Survival
8%
Minimal Residual Disease
9%
Myelodysplastic Syndrome
14%
Myeloid Blasts
5%
Newly Diagnosed
27%
Older Adults
5%
Older Patients
7%
Overall Response Rate
7%
Overall Survival
24%
Phase II Study
12%
Phase II Trial
13%
Propensity Score Analysis
6%
RAS mutant
5%
Refractory AML
5%
Relapsed or Refractory
13%
Relapsed or Refractory Acute Myeloid Leukemia
21%
Secondary Acute Myeloid Leukemia (sAML)
6%
Treatment Regimen
5%
Treatment Strategy
6%
Tumor Protein p53 (TP53)
5%
Unfit Patients
7%
Venetoclax
70%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
5%
Acute Myeloid Leukemia
82%
Adverse Event
5%
Azacitidine
8%
Chemotherapy
30%
Chronic Myeloid Leukemia
9%
Clinical Trial
5%
Decitabine
18%
Diseases
7%
Enasidenib
5%
Event Free Survival
5%
Leukemia
10%
Malignant Neoplasm
8%
Minimal Residual Disease
8%
Myelodysplastic Syndrome
13%
Myeloid Leukemia
7%
Overall Survival
23%
Philadelphia 1 Chromosome
5%
Protein Tyrosine Kinase Inhibitor
9%
Remission
17%
Secondary Acute Myeloid Leukemia
6%
Venetoclax
59%
Medicine and Dentistry
Acute Myeloid Leukemia
83%
Allogeneic Stem Cell Transplantation
6%
Cancer
7%
Cedazuridine
5%
Chronic Myelogenous Leukemia
6%
Decitabine
24%
Event Free Survival
8%
Hazard Ratio
5%
Hypomethylating Agent
18%
Induction Chemotherapy
8%
Infection
5%
Leukemia
9%
Malignant Neoplasm
6%
Meta-Analysis
5%
Minimal Residual Disease
8%
Myelodysplastic Syndrome
8%
Myeloid Leukemia
7%
Neoplasm
5%
Overall Survival
30%
Pediatrics
5%
Recurrence Free Survival
5%
Secondary Acute Myeloid Leukemia
5%
Tyrosine-Kinase Inhibitor
9%
Venetoclax
62%